Phaseline

Companies › Beijing Immunochina Medical Science & Technology

Beijing Immunochina Medical Science & Technology: clinical trials, targets and expected readouts

2 active drug programs in 23 registered trials: 14 Phase 2, 9 Phase 1; Oncology, Neurology, Hematology; next expected readout Jun 2035.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fludarabine Phosphate (IM19)
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia …Jun 2035
IM96 CAR-T Cells
CAR-T cell therapy targeting unknown antigen
–Phase 1Colorectal Cancer (CRC)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03509961Fludarabine Phosphate (IM19)Phase 2B-cell Acute Lymphoblastic LeukemiaOncologyJul 2025
NCT06718738IM96 CAR-T CellsPhase 1Colorectal Cancer (CRC)OncologyAug 2025
NCT05832515Fludarabine Phosphate (IM19)Phase 1Multiple SclerosisNeurologyDec 2026
NCT00544466Fludarabine Phosphate (IM19)Phase 1LeukemiaOncologyDec 2026
NCT00920972Fludarabine Phosphate (IM19)Phase 1Metabolic DisordersOncologyDec 2026
NCT06098326Fludarabine Phosphate (IM19)Phase 2Myelodysplastic SyndromesHematologyDec 2026
NCT05126849Fludarabine Phosphate (IM19)Phase 2Refractory Idiopathic Aplastic AnemiaHematologyJan 2027
NCT06834529Fludarabine Phosphate (IM19)Phase 1Relapsed or Refractory B Cell Leukemia and LymphomaOncologyJan 2027
NCT04262843Fludarabine Phosphate (IM19)Phase 2Acute Lymphoblastic LeukemiaOncologyMay 2027
NCT03192397Fludarabine Phosphate (IM19)Phase 1Acute Myeloid Leukemia in RemissionOncologyMay 2027
NCT07232953Fludarabine Phosphate (IM19)Phase 2Acute Myeloid Leukaemia (AML)OncologyJun 2027
NCT07232953Fludarabine Phosphate (IM19)Phase 2Acute Myeloid Leukaemia (AML)OncologyJun 2027
NCT02250937Fludarabine Phosphate (IM19)Phase 2Acute Myeloid LeukemiaOncologyOct 2027
NCT07410494Fludarabine Phosphate (IM19)Phase 1CancerOncologyDec 2027
NCT07410494Fludarabine Phosphate (IM19)Phase 1CancerOncologyDec 2027
NCT02629809Fludarabine Phosphate (IM19)Phase 2Chronic Lymphocytic LeukemiaOncologyMar 2028
NCT06869265Fludarabine Phosphate (IM19)Phase 2Acute Myeloid Leukemia (AML)OncologyApr 2028
NCT03980769Fludarabine Phosphate (IM19)Phase 2Non-Neoplastic Hematopoietic and Lymphoid Cell DisorderOncologyJul 2028
NCT02861417Fludarabine Phosphate (IM19)Phase 2Hematopoietic and Lymphoid Cell NeoplasmOncologyAug 2028
NCT00801489Fludarabine Phosphate (IM19)Phase 2Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11HematologyOct 2028
NCT06013423Fludarabine Phosphate (IM19)Phase 2Acute Leukemia of Ambiguous LineageOncologyOct 2031
NCT07582172Fludarabine Phosphate (IM19)Phase 2Acute Myeloid Leukemia With Complex KaryotypeOncologyNov 2031
NCT04440436Fludarabine Phosphate (IM19)Phase 1NHLOncologyJun 2035

Targets

RRM1 (1) RRM2B (1) RRM2 (1) POLA1 (1) POLD4 (1)

Companies with the same targets

Jiangsu Healthy Life Innovation Medical Technology Theravia InnoPharmax Jiangsu Hansoh Pharmaceutical Gilead Sciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.